Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Amato

Showing results (451-460 of 482) with videos related to

Pageof 49
Sort By:
Techniques in Coloproctology|February 15, 2017
T1 colon cancer in the era of screening: risk factors and treatmentF Bianco, S De Franciscis, A Belli, et al.
Journal for Immunotherapy of Cancer|July 20, 2021
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitorsAmanda C Guidon, Leeann B Burton, Bart K Chwalisz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 7, 2017
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|October 29, 2017
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
RMD Open|November 28, 2017
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportMatteo Bottai, Anna Tjärnlund, Giola Santoni, et al.
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Pageof 49

Showing results (451-460 of 482) with videos related to

Sort By:
Pageof 49
Techniques in Coloproctology|February 15, 2017
T1 colon cancer in the era of screening: risk factors and treatmentF Bianco, S De Franciscis, A Belli, et al.
Journal for Immunotherapy of Cancer|July 20, 2021
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitorsAmanda C Guidon, Leeann B Burton, Bart K Chwalisz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 7, 2017
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|October 29, 2017
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
RMD Open|November 28, 2017
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportMatteo Bottai, Anna Tjärnlund, Giola Santoni, et al.
The Lancet. Neurology|August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trialMichael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
Neurology|July 3, 2020
Minimal manifestation status and prednisone withdrawal in the MGTX trialIkjae Lee, Hui-Chien Kuo, Inmaculada B Aban, et al.
The Lancet. Neurology|January 30, 2019
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trialGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Neurology|February 18, 2021
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENTAnthony A Amato, Michael G Hanna, Pedro M Machado, et al.
The New England Journal of Medicine|August 11, 2016
Randomized Trial of Thymectomy in Myasthenia GravisGil I Wolfe, Henry J Kaminski, Inmaculada B Aban, et al.
Pageof 49